BridgeBio Oncology director granted 7,289 options

BridgeBio Oncology Therapeutics director Peter F. Lebowitz received a grant of stock options covering 7,289 shares of common stock.

Rhea-AI Filing Summary

BridgeBio Oncology Therapeutics director Peter F. Lebowitz received a grant of stock options covering 7,289 shares of common stock. The options have an exercise price of $7.73 per share and expire on June 15, 2036. According to the terms, they vest in full on the earlier of the first anniversary of the grant date or the next Annual Meeting of Stockholders, provided he continues serving the company through that vesting date. After this grant, Lebowitz holds 7,289 stock options directly.

Insider Trade Summary

Grant/Award: 7,289 shares

Grant/Award 1 txn

Insider Lebowitz Peter F

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (Right to Buy)	7,289	$0.00	$0.00

Holdings After Transaction: Stock Option (Right to Buy) — 7,289 contracts (Direct)

Footnotes (1)

1. F1. The shares underlying the stock option vest in full upon the earlier of (i) the first anniversary of the date of grant or (ii) the date of the next Annual Meeting of Stockholders of the Issuer following the date of grant, subject to the Reporting Person's continued service to the Issuer through the applicable vesting date.

Key Figures

Option grant size: 7,289 options Exercise price: $7.73 per share Expiration date: June 15, 2036 +2 more

5 metrics

Option grant size 7,289 options Stock Option (Right to Buy) granted to director on June 16, 2026

Exercise price $7.73 per share Conversion or exercise price for the 7,289 stock options

Expiration date June 15, 2036 Expiration of the granted stock options

Underlying shares 7,289 shares Common stock underlying the stock option grant

Post-grant derivative holdings 7,289 options Total stock options held directly after the transaction

Key Terms

Stock Option (Right to Buy), Common Stock, Annual Meeting of Stockholders, vesting

4 terms

Stock Option (Right to Buy) financial

"security_title: Stock Option (Right to Buy)"

Common Stock financial

"underlying_security_title: Common Stock"

Common stock represents ownership shares in a company, giving investors a stake in its success and a say in important decisions through voting rights. It is the most common type of stock traded on markets and can provide income through dividends, as well as potential for value growth. For investors, holding common stock means sharing in the company’s profits and risks.

Annual Meeting of Stockholders financial

"the date of the next Annual Meeting of Stockholders of the Issuer"

vesting financial

"The shares underlying the stock option vest in full upon the earlier of"

Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did BridgeBio Oncology Therapeutics (BBOT) disclose in this Form 4?

BridgeBio Oncology Therapeutics reported a director stock option grant for 7,289 shares. The options were awarded to Peter F. Lebowitz as compensation and give him the right to buy common stock at a fixed exercise price of $7.73 per share.

Who is the insider involved in the BBOT stock option grant?

The insider is Peter F. Lebowitz, a director of BridgeBio Oncology Therapeutics. He received a grant of stock options for 7,289 underlying common shares, held directly, as part of his service-related compensation with the company’s board.

What are the key terms of Peter Lebowitz’s BBOT stock options?

The stock options cover 7,289 shares of common stock at a $7.73 exercise price. They expire on June 15, 2036 and vest in full once a specific service-based vesting condition tied to time and the next Annual Meeting is met.

When do the BBOT stock options granted to Peter Lebowitz vest?

The options vest in full on the earlier of the first anniversary of the grant date or the next Annual Meeting of Stockholders. Vesting is contingent on Peter Lebowitz continuing to serve the company through the applicable vesting date.

How many BBOT derivative securities does Peter Lebowitz hold after this Form 4?

Following this transaction, Peter Lebowitz directly holds stock options covering 7,289 shares of BridgeBio Oncology common stock. This single grant represents his reported derivative holdings in this filing, with no additional option positions listed.

Does this BBOT Form 4 show any stock being bought or sold on the market?

No open-market buys or sells are reported. The Form 4 records a grant of stock options to director Peter Lebowitz as compensation, giving him future purchase rights rather than showing an immediate market purchase or sale of common shares.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 06/18/2026 - 04:57 PM EDT Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Lebowitz Peter F

(Last) (First) (Middle)

BRIDGEBIO ONCOLOGY THERAPEUTICS, INC.

256 EAST GRAND AVENUE, SUITE 104

(Street)

SOUTH SAN FRANCISCO CALIFORNIA 94080

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
BridgeBio Oncology Therapeutics, Inc. [ BBOT ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/16/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$7.73	06/16/2026		A		7,289		(1)	06/15/2036	Common Stock	7,289	$0	7,289	D

Explanation of Responses:

1. The shares underlying the stock option vest in full upon the earlier of (i) the first anniversary of the date of grant or (ii) the date of the next Annual Meeting of Stockholders of the Issuer following the date of grant, subject to the Reporting Person's continued service to the Issuer through the applicable vesting date.

Remarks:

Exhibit 24 - Power of Attorney

	/s/ Aaron Chan, Attorney-in-Fact	06/18/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)